Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Day One Biopharmaceuticals, Inc. - Common Stock (NQ:DAWN)

10.74 -0.42 (-3.76%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Day One Biopharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Day One to Participate in the Piper Sandler 34th Annual Healthcare Conference
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Announces Upcoming Presentations at 2022 Society for Neuro-Oncology Annual Meeting
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Day One Reports Third Quarter 2022 Financial Results and Corporate Progress
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Insiders Buy Over $540M Of 2 Stocks ↗
Although the US stocks closed slightly lower on Wednesday, there were a few notable insider trades. 
Via Benzinga
News headline image
Why Is Day One Biopharmaceuticals (DAWN) Stock Up 103% Today? ↗
Today's announcement of positive clinical trial results for a key pediatric tumor drug has DAWN stock more than doubling on Monday. 
Via InvestorPlace
News headline image
Day One Announces Cooperative Research and Development Agreement with National Cancer Institute to Expand Development of Tovorafenib (DAY101)
From Day One Biopharmaceuticals, Inc.
Via GlobeNewswire
Central Nervous System Disorders Therapeutics Market Expected to Reach $159 Billion by 2028
Palm Beach, FL –– October 12, 2022 – FinancialNewsMedia.com News Commentary – The COVID pandemic has not only had a negative effect on most markets but it has also spurred growth in several worldwide... 
Via FinancialNewsMedia
News headline image
5 Value Stocks In The Healthcare Sector ↗
What is a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators... 
Via Benzinga
News headline image
Why Twin Vee Powercats Is Trading Higher By Around 90%, Here Are 84 Stocks Moving In Friday's Mid-Day Session ↗
Gainers Twin Vee Powercats Co. (NASDAQ: VEEE) shares jumped 90% to $7.60 after the company said Q2 sales results were up year over year. 
Via Benzinga
News headline image
Why Embark Technology Jumped Around 85%; Here Are 108 Biggest Movers From Friday ↗
Gainers Embark Technology, Inc. (NASDAQ: EMBK) jumped 84.8% to close at $1.07 on Friday after the company reported better-than-expected Q2 EPS results. 
Via Benzinga
News headline image
LegalZoom.com, Toast And Some Other Big Stocks Moving Higher On Friday ↗
  WeTrade Group, Inc. (NASDAQ: WETG) jumped 46% to $20.56 after the company announced it entered into a sales agreement with Parkway Medical Limited to sell monkeypox virus test kits and antigen tests... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Gainers NeuroBo Pharmaceuticals (NASDAQ:NRBO) shares increased by 15.1% to $0.63 during Wednesday's after-market session. The company's market cap stands at $16.7 million. 
Via Benzinga
News headline image
Biotech ETF Tops in June: 5 Stocks That Outperform ↗
Although most of the stocks in BBC’s portfolio have delivered strong returns this year so far, a few have gained more than 45%. 
Via Talk Markets
News headline image
The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Day One Biopharmaceuticals Stock Scores Rising Relative Strength Upgrade ↗
Day One Biopharmaceuticals stock, which saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, rising from 83 to 92. 
Via Investor's Business Daily
News headline image
The Daily Biotech Pulse: FDA Committee Backs Moderna Shot For 5-17 Years, 180 Life Sciences Stock Plunges, Pfizer's Posts Disappointing Paxlovid Data ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
DAWN Stock Is in the Spotlight as Day One Announces Common Stock Offering ↗
Day One Biopharmaceuticals (DAWN) stock is in the news Tuesday as a common stock offering has the company's shares moving. 
Via InvestorPlace
News headline image
The Daily Biotech Pulse: FDA Nod For Lilly-Incyte's Patchy Hair Loss Treatment, First Regulatory Submission For EQRx, Soleno's Promising Data From Prader-Willi Candidate ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Tuesday ↗
Piper Sandler reduced Braze, Inc. (NASDAQ: BRZE) price target from $65 to $42. Tesla shares rose 5.8% to $31.10 in pre-market trading. 
Via Benzinga
News headline image
Mid-Afternoon Market Update: Gold Down Over 2%; Electric Last Mile Solutions Shares Plummet ↗
U.S. stocks traded lower toward the end of trading, with the S&P 500 dropping by more than 3% on Monday. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
93 Biggest Movers From Yesterday ↗
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares surged 126% to close at $14.96 on Monday after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in... 
Via Benzinga
News headline image
S&P 500 Slips Into Bear Market Territory As Selling Intensifies ↗
The S&P 500 Index has finally plunged into a bear market territory, marked by a more than 20% deficit from its January record highs. 
Via Talk Markets
News headline image
Day One Biopharmaceuticals Scores Triple-Digit Gain With Bullish Numbers In Brain Cancer ↗
Day One says 91% of patients benefitted from its experimental treatment. 
Via Investor's Business Daily
News headline image
Mid-Day Market Update: Nasdaq Dips Over 400 Points; Day One Biopharmaceuticals Shares Jump ↗
U.S. stocks traded lower midway through trading, with the Nasdaq Composite tumbling by more than 400 points on Monday. 
Via Benzinga
News headline image
Mid-Morning Market Update: Markets Open Lower; Dow Drops 600 Points ↗
U.S. stocks traded lower this morning, with the Dow Jones dropping more than 600 points on Monday. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
70 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN) shares jumped 110% to $13.93 after the company announced initial data from the pivotal FIREFLY-1 trial of tovorafenib in relapsed pediatric... 
Via Benzinga
News headline image
Why Day One Biopharma Shares Are Surging Today ↗
Day One Biopharmaceuticals (NASDAQ: DAWN) shares are surging on initial data from the first 22 evaluable patients in the Phase 2 FIREFLY-1 trial for tovorafenib (DAY101) in relapsed or progressive... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.